Amgen, J&J win a round in anemia controversy

An FDA expert committee has rejected a proposal to set a clear limit on the use of anemia drugs made by Amgen and Johnson & Johnson. One regulator remarked that there was no consensus on a target for a recommended dose. The rejection marks a victory for both companies, which has seen their revenue drop after safety issues regarding anemia drugs were raised. The FDA says it expects to finalize label changes on anemia drugs in a matter of days.

- read the report from The Wall Street Journal (sub. req.)

Related Articles:
Amgen wins a round in anemia ruckus. Report
Amgen discusses the future with analysts. Report
New rules limit use of anemia drugs. Report
J&J makes cuts at Alza and Scios. Report
New study points to danger of anemia drug. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.